CYT 006 AngQb

Drug Profile

CYT 006 AngQb

Alternative Names: Anti-angiotensin II vaccine - Cytos; CYT 006 AngQb Immunodrug™; CYT006-AngQb; Hypertension virus-like particle vaccine - Cytos

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Class Antihypertensives; Oligopeptides; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 17 Aug 2011 Suspended - Phase-II for Hypertension in Germany (SC)
  • 17 Aug 2011 Suspended - Phase-II for Hypertension in Switzerland (SC)
  • 12 Nov 2009 Cytos Biotechnology updates on the development of the hypertension vaccine CYT 006 AngQb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top